Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03598309 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers
A Phase 2 study of Lung Diseases and Lung Cancer, Protection Against, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT03598309: Active Phase 2 study of Lung Diseases and Lung Cancer, Protection Against, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT03598309 is a Phase 2 study of Lung Diseases and Lung Cancer, Protection Against that is active but no longer recruiting, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 19 participants, below the 739-participant average among 31 other Lung Diseases trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03598309, a Phase 2 study of Lung Diseases and Lung Cancer, Protection Against, is active but no longer recruiting, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out if an investigational combination drug called Lovaza (made with fish oils)+Curcumin C3 Complex (made from a root called curcumin) can help reduce the size of lung nodules. Researchers also want to find out if the combination of Lovaza+Curcumin C3 Complex is safe and tolerable.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Curcumin C3 complex®
- DRUG Lovaza®
Study Locations (1)
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2019-06-05 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03598309
The ClinicalTrials.gov registry entry for NCT03598309 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 739-participant average among 31 other Lung Diseases trials with a reported enrollment target (97% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lung Diseases appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03598309 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT03598309 about?
NCT03598309 is a clinical study titled "Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers". The purpose of this study is to find out if an investigational combination drug called Lovaza (made with fish oils)+Curcumin C3 Complex (made from a root called curcumin) can help reduce the size of lung nodules. Researchers also want to find out if the combination of Lovaza+Curcumin C3 Complex is s...
What is the current status of trial NCT03598309?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2019-06-05. Estimated completion is 2026-05.
What conditions does trial NCT03598309 study?
This clinical trial studies the following conditions: Lung Diseases, Lung Cancer, Protection Against.
What interventions are being tested in trial NCT03598309?
The interventions under investigation include: Placebo (OTHER), Curcumin C3 complex® (DRUG), Lovaza® (DRUG).
Who is sponsoring clinical trial NCT03598309?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03598309 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
RECRUITING · Phase 2
-
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RECRUITING · Phase 2
-
A Study of Mosliciguat in PH-ILD
ACTIVE NOT RECRUITING · Phase 2
-
A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.
COMPLETED · Phase 2
-
Real World Registry for Use of the Ion Endoluminal System
RECRUITING
-
American Lung Association (ALA) Lung Health Cohort
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00003537 · 19 participants · Phase 2
Antineoplaston Therapy in Treating Adult Patients With Anaplastic Astrocytoma
- NCT00006342 · 19 participants
Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor
- NCT00031694 · 19 participants · Phase 2
Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer
- NCT00061620 · 19 participants · Phase 1
Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies
Similar registry start date
- NCT05684068 · started 2028-08 · NA
Dimensional Changes: Randomized Clinical Trial
- NCT07167953 · started 2028-08 · NA
The Spiral MRI Study
- NCT07215013 · started 2028-07 · NA
Acoustic Resonance Therapy for Treating Empty Nose Syndrome
- NCT07443332 · started 2028-07 · NA
Culturally Adapted Contingency Management
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.